Origin Bio Analysis: $15M Raised
What is Origin Bio?
Origin Bio maps cancer biology by perturbing real patient tumor tissue and measuring responses at the molecular level. The company combines tissue collection, precision slicing, multimodal readouts, and AI training into a single research workflow. It cites use in target identification, in-silico drug screening, patient stratification, and biomarker discovery.
Location
San Francisco, United States
Employees
1-10
Founded
2025
Industry
Healthcare, Drug Discovery And Delivery
Business Model v4
Biotech
Delivery Model
Developer platform / API / infra
YC Batch
W26
YC Partner
Ankit Gupta
How much Origin Bio raised
Funding - $15.0M
Who are the founders of Origin Bio
YR
Yash Rathod
CEO
Product Description
Origin Bio's main product offering is the Axis multifunctional DNA model, which utilizes AI technology to enhance the safety and efficacy of cell therapies. Key features of Axis include its ability to generate and predict regulatory DNA elements, outperforming existing models like DeepMind’s AlphaGenome by 6.7% in predicting regulatory element binding activity. The model integrates tasks related to DNA-to-DNA, DNA-to-function, and function-to-DNA, providing a comprehensive tool for biotechnology researchers. The benefits of using Axis include improved precision in gene expression control, which can lead to safer and more effective gene therapies, ultimately reducing failure rates in clinical trials.
See something that needs updating? Suggest edits to this profile.